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Abstract
Management of cancers of the digestive system has 
progressed rapidly into the molecular era. Despite 
the significant recent achievements in the diagnosis 
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and treatment of these patients, the number of 
deaths for these tumors has currently plateaued. 
Many investigations have assessed the role of HER2 
in tumors of the digestive system in both prognostic 
and therapeutic settings, with heterogeneous results. 
Novel testing and treatment guidelines are emerging, 
in particular in gastric and colorectal cancers. However, 
further advances are needed. In this review we provide 
a comprehensive overview of the current state-of-
knowledge of HER2  alterations in the most common 
tumors of the digestive system and discuss the opera-
tional implications of HER2 testing. 
Key words: HER2; Digestive system; Gastrointestinal 
tract; Gastric cancer; Colon cancer; Esophageal cancer; 
Gastroesophageal junction cancer; Biliary tract cancer; 
Gallbladder cancer; Liver cancer; Pancreas cancer
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Core tip: Numerous studies have broadened our under-
standing of HER2 as a critical oncogene in many human 
cancers, including tumors of the digestive system. 
Due to the increasing importance of HER2  testing in 
this heterogeneous group of tumors, in this review we 
seek to outline the current state of knowledge of HER2 
alterations in the most common malignancies occurring 
in the digestive system, to examine the operational impli-
cations of HER2 testing as a biomarker and potentially 
targetable gene, and discuss immediate future perspec-
tives for pathologists and gastroenterologists.
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INTRODUCTION
The epidermal growth factor receptor 2 is a proto-
oncogene that was first identified in the early 1980s 
in rodent neural tumor cell lines and therefore named 
neu[1]. Given the homology between the human gene 
and that of the rodent, adherence to appropriate 
nomenclature is pivotal to avoid any confusion. In 
this review, HER2/neu will refer to the gene across 
both species, while HER2 and erbB2 will be used 
specifically to indicate the human gene and its protein 
product, respectively[2]. HER2/neu belongs to one of 
the most studied growth factor receptor systems in 
cancer, the erbB tyrosine kinase family[1-4]. This family 
consists of four members encoding the homologous 
epidermal growth factor receptor proteins erbB1, 
2, 3, 4 that are ubiquitously expressed in epithelial, 
mesenchymal, and neuronal normal cells and their 
cellular progenitors[5,6]. Each of these receptors is 
composed of an extracellular ligand-binding domain, a 
transmembrane segment and an intracellular protein 
kinase domain with a carboxyl terminal segment 
holding site of phosphorylation or tyrosine residues 
(Figure 1)[5,7,8]. Among the four erbB proteins, erbB2 is 
functionally characterized by an extraordinarily strong 
catalytic kinase activity, representing a key oncoprotein 
that triggers cornerstone intracellular signaling events 
for cell growth and survival, ultimately leading to 
increased signal transduction and activation of the 
MAPK and PI3K/Akt pathways[4,6,9]. Importantly, erbB2 
is not involved in ligand binding of the growth factors 
unless is overexpressed[10], while the other members of 
its family represent active receptors in basal conditions 
also[5,9], as outlined in Figure 1. 
Numerous preclinical and clinical studies, beginning 
with the intuition of Slamon and collaborators on 
the role of HER2 in breast cancer, have broadened 
our understanding of this oncogene in many human 
cancers, including digestive system cancers (DSC)[8,11]. 
While HER2 represents a prognostic marker of 
aggressive behavior in many DSC[8,12,13], the importance 
of this oncogene remains closely related to its role as 
a potentially targetable cancer gene[4,14]. To date, anti-
HER2 antibodies such as trastuzumab, pertuzumab, 
the new conjugate ado-trastuzumab emtansine, and 
HER2-inhibitors (e.g., lapatinib) have received the 
United States Food and Drug Administration (FDA) 
approval not only in HER2-positive breast cancers 
but also in HER2-positive metastatic gastric cancer 
(GC)[15]. Massively parallel sequencing studies have 
recently revealed that a substantial proportion of DSC 
are genetically characterized by HER2 alterations 
(Figure 2)[16]. However, highly different percentages in 
the incidence of these molecular aberrations, ranging 
from 0 to 50%, have been reported even within the 
same anatomic site, such as the pancreas (Table 
1)[16-19]. These partially discordant observations could 
have been, at least in part, responsible for the nihilistic 
view of HER2 in the targeted therapeutic regimens 
for extra-gastric DSC. Many groups are currently 
establishing the role of HER2 in DSC in both prognostic 
and therapeutic settings. However, targeting of tumors 
that overexpress erbB2, albeit representing the reality 
for advanced GC and gastroesophageal junction (GEJ) 
cancer, is considered a reasonable future option[8,20]. 
At present, the role of trastuzumab in DSC is being 
explored by a variety of translational research mole-
cular pathology studies, as well as clinical trials. 
Management of DSC has progressed rapidly into 
the molecular era[21-30]. However, the “trastuzumab-
revolution” that we have experienced in the breast 
has yet to be realized in the digestive system tract 
and its accessory organs[8,31]. Due to the increasing 
importance of HER2 testing in cancer and the new 
exciting challenges that precision medicine is providing, 
in this review we seek to describe the current state of 
knowledge of HER2 alterations in the most common 
DSC, to discuss the operational issues of HER2 testing, 
and to outline forthcoming clinical perspectives, in 
particular focusing on the cutting-edge tools available 
for HER2 characterization and targeting in the digestive 
system.
HER2 TESTING IN THE DIGESTIVE 
SYSTEM
Esophageal cancer
Esophageal cancer (EC), excluding GEJ tumors, is 
among the ten most prevalent tumors worldwide and 
ranks fifth in cancer mortality in men and eighth in 
women[32]. Squamous cell carcinoma (SCC) represents 
the most frequent histological type[20]. The poor 
prognosis of EC results from the delayed diagnosis 
and poor efficacy of current treatments, being in most 
cases limited to a palliative role[23]. In the largest 
meta-analysis of the prognostic significance of erbB2 
overexpression and gene amplification in EC patients, 
22% of tumors were HER2-positive, regardless of 
histotype[33]. However, these data are likely to be 
overestimated. Indeed, the overexpression of erbB2 
has been observed in 12%-17% of adenocarcinomas 
(ADC) in more recent studies[34], whereas less than 
4% of esophageal SCCs are HER2-amplified[35]. Taken 
together, no significant differences in survival rates 
have been reported in patients diagnosed with HER2-
positive esophageal ADC compared with the HER2-
negative cases. However, the great heterogeneity 
among indexed studies on HER2 prognostic role in 
these malignancies demands further investigations. 
Interestingly, the prognostic influence of HER2 
amplification as a biomarker is slightly greater in SCC 
compared to ADC[33,35]. On the other hand, the small 
number of HER2-positive SCCs, the lack of large-
Fusco N et al . HER2  in digestive system cancers
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cohort studies, and the absence of standardized 
methods for HER2 testing limit our knowledge of HER2 
significance in SCC of the esophagus[36]. At present, the 
optimal treatment for EC remains controversial. In this 
regard, neoadjuvant chemotherapy with subsequent 
surgery represent the standard approach in the 
United Kingdom[37,38], whereas in Europe and United 
States neoadjuvant chemo-radiotherapy followed by 
surgery is preferred[39]. However, the individualization 
and optimization of therapy for EC might come 
across HER2 and its epistatic interactions with other 
potentially actionable cancer genes. Indeed, it has 
recently been reported that possible alterations in 
epidermal growth factor receptor (EGFR), telomerase 
reverse transcriptase (TERT), and HER2 are bona 
fide predictor of response to HER2-target therapy in 
EC, particularly in SCCs[35,40]. At present, RTOG 1010 
(Radiation Therapy, Paclitaxel, and Carboplatin With 
or Without Trastuzumab in Treating Patients With EC) 
is the only ongoing phase Ⅲ trial (https://clinicaltrials.
gov/ct2/show/study/NCT01196390) randomizing 
patients with HER2-positive esophageal ADC to 
chemoradiation with or without trastuzumab. 
Gastric and gastroesophageal junction cancer
GC, including GEJ cancer, is closely related to environ-
mental factors, reflecting its characteristic geographical 
distribution[32]. Although GC rates have gradually 
decreased during the past decades, this tumor still 
represents the third leading cause of cancer-related 
death globally[32]. The vast majority of GCs can be 
divided into three distinct subtypes based on Lauren’s 
histopathologic classification: intestinal-type, showing 
glandular architecture, diffuse-type, with poorly 
cohesive cells arranged in an infiltrative pattern, and 
mixed-type, bearing hybrid characteristics[20]. This 
morphologic heterogeneity replicates an intrinsic 
molecular complexity. Recently, The Cancer Genome 
Atlas (TCGA) network proposed a novel molecular 
classification of GC, dividing these tumors into four 
major molecular subtypes, namely tumors positive 
for Epstein-Barr, microsatellite unstable tumors, geno-
mically stable tumors, and tumors with chromosomal 
instability[41]. Among these molecular subgroups, 
microsatellite unstable tumors preferentially occur 
in the body and antrum, and are characterized by 
an extraordinarily high number of mutations with 
the lack of targetable amplifications, including HER2 
amplification. Chromosomal instability subtype encom-
passes the majority of GC, has a predilection for the 
GEJ, is associated with intestinal-type histology, and 
exhibit the highest rates of HER2 amplification among 
all molecular subtypes[41]. Overall, GCs overexpressing 
erbB2 and/or showing HER2 amplification, range from 
13% to 22% of cases[12,42]. Meta-analysis data suggest 
that GC harboring HER2 amplification fares worse[43]; 
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Figure 1  Schematic representation of the human erbB receptors in basal condition. The extracellular portion of each receptor consists of four domains (Ⅰ-
Ⅳ). Both domains Ⅰ and Ⅲ, which are related leucine-rich segments, actively participate in ligand binding, except for those of erbB2. Domains Ⅱ and Ⅳ contain 
numerous cysteine residues and participates in dimer formation. The kinase domain of erbB3 is kinase-impaired. The growth factor groups that bind each receptor 
are indicated on the top. PKD: Protein kinase domain; EGF: Epidermal growth factor; EPG: Epigen; TGFa: Transforming growth factor-a; AR: Amphiregulin; BTC: 
Betacellulin; HB-EGF: Heparin-binding epidermal growth-factor like growth factor; EPR: Epiregulin; Nrg-1/2/3/4: Neuregulin-1/2/3/4. 
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cells[12,46]. From a therapeutic perspective, it is currently 
recommended to administer trastuzumab in combi-
nation with cytotoxic therapies in HER2-positive GC 
patients[42]. In this setting, the addition of trastuzumab 
to chemotherapy increased the objective response rate 
from 35% to 47%, improving progression-free survival 
from 5.5 mo to 6.7 mo and overall survival from 11.1 
mo to 13.8 mo[5,42,47]. Clinical trials aiming to examine 
the efficacy of lapatinib in combination with paclitaxel 
compared with paclitaxel alone in the treatment of 
HER2-positive GC are on-going (https://clinicaltrials.
gov/ct2/show/study/NCT01705340). Other clinical trials 
are currently exploring the effect of adding pertuzumab 
to chemotherapy (https://clinicaltrials.gov/ct2/show/
study/NCT01461057) and comparing trastuzumab to 
paclitaxel or docetaxel as second-line treatment (https://
clinicaltrials.gov/ct2/show/study/NCT01641939). 
Colorectal cancer
Colorectal cancer (CRC) is a major contributor to 
however, the prognostic value of HER2 remains con-
troversial in the stomach[44-46]. This is probably due to 
the heterogeneous HER2 status patterns in tumors 
arising in the stomach that basically mirror the intra-
tumor morphologic and molecular heterogeneity of GC 
(Figure 3)[12]. Indeed, in contrast to breast carcinoma, 
up to 90% of erbB2-positive GCs are reported to 
harbor erbB2 overexpression in less than 5% of tumor 
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Figure 2  HER2 alterations frequencies from public datasets accessible from cBioPortal[16] in the most common tumors occurring in the digestive system 
compared to breast cancer. Overall, HER2 amplifications occur more frequently in gastric, esophageal, and pancreatic cancers, whereas gallbladder cancer and 
cholangiocarcinoma characteristically show HER2 mutations (10% and 6% of cases, respectively). The domain structure of the erbB2 protein and gene alterations 
identified in primary carcinomas of the digestive system available from cBioPortal[16] (reported the top) show the presence of hotspot somatic mutations in the furin-like 
(binding site) and protein kinase domains. Mutation types are color-coded on the basis of the legend on the bottom right.
Table 1  erbB2 overexpression and gene amplification reported 
frequencies in tumors of the digestive system
Primary tumor erbB2 
overexpression 
frequencies
HER2 
amplification 
frequencies
Ref.
Esophageal cancer   4%-22%   4%-14% [33-36,38,39]
Gastric cancer 13%-22% 10%-18% [12,41-47]
Colorectal cancer   2%-11% 3% [48-57]
Biliary tract cancer   5%-76% 1%-8% [27,75,86,88-90]
Pancreatic cancer   0%-50%   2%-29% [17-19,64-66,68]
Liver cancer 2%-5% 0-1% [72-79]
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cancer morbidity and mortality, with 1.36 million new 
cases and more than half million deaths per year 
worldwide[32]. Several studies assessed HER2 status 
in CRC, with some authors reporting membranous 
erbB2 overexpression in 2%-11% and others reporting 
cytoplasmic overexpression in 47%-68% of cases[48-52]. 
However, it is currently acknowledged that the amp-
lification of HER2 occurs in only 3% of CRC[53]. In 
accordance to this notion, a recent comprehensive 
genomic characterization of CRC revealed a recurrent 
amplicon at 17q21.1 in 4% of these tumors[54]. This 
locus contains seven genes, including HER2[55]. The 
operational implications of HER2 amplification in CRC, 
however, remain elusive, with a number of studies 
reporting contradictory links to prognosis[53,56,57]. How to 
assess HER2 status in CRC cancer remains a matter of 
debate among pathologists; however, a panel of HER2 
experts recently provided a reproducible and rigorous 
testing algorithm[57]. Intriguingly, no intra-tumor 
heterogeneity is described in CRC except for anecdotic 
reports[57]. Albeit HER2 seems not to represent a 
reliable prognostic marker in CRC, this molecular 
alteration is strongly associated with wild-type status 
of Kirsten rat sarcoma viral oncogene homolog 
(KRAS) and amplification DNA topoisomerase 2-alpha 
(TOP2A)[16,58,59]. This observation is not trivial, raising 
the hypothesis that HER2 amplification might be a bona 
fide alternative driver of Ras-Raf-MEK-ERK pathway 
activation in CRC. In contrast to HER2, intratumor 
heterogeneity of KRAS mutation status is reported and 
crucial in selecting patients for anti-EGFR therapy in 
CRC[12]. For these reasons, and given the homogeneity 
in erbB2 expression, it has recently been proposed 
that HER2 status should be assessed as a putative 
biomarker of resistance to anti-EGFR therapy in KRAS 
wild-type patients and, if further studies confirm that 
TOP2A amplifications are associated with anthracycline 
sensitivity, as a predictor to response[57,59,60]. At present, 
results from phase Ⅱ and Ⅲ trials suggest that HER2-
positive CRC should be treated with trastuzumab[61]. 
Pancreatic ductal adenocarcinoma
Pancreatic cancer (PC) accounts for approximately 2% 
of new cancers, and is responsible for 7% of cancer-
related death yearly worldwide[32]. The vast majority 
of PCs is represented by invasive ductal ADC arising in 
the head of the gland; 20% of cases involve the body 
or the tail[20]. The poor prognosis for these patients 
is attributed to delayed diagnosis, early metastasis, 
and the limited efficacy of available systemic treat-
ments[62]. Systemic therapies are only modestly 
effective; however, there is emerging evidence that 
small groups of patients may respond well to specific 
treatments. Amplification of HER2 gene and/or 
overexpression of its product have been implicated 
in the development of PC[63]. However, the reported 
rates of erbB2 overexpression in these neoplasms 
are extremely variable, ranging from 0 to 50% of 
cases[17-19,64]. Furthermore, the prognostic role of HER2 
amplification in PC has been investigated in numerous 
studies, again, with heterogeneous results[63]. As a 
consequence, the diagnostic criteria and prevalence of 
HER2 amplification in pancreatic ductal ADC remain 
unclear. Preclinical studies support the potential 
efficacy of trastuzumab in PC[65,66], although clinical 
trials have been disadvantaged by small cohorts[67,68]. 
In one phase Ⅱ trial, 17 patients showing HER2 
amplification were treated with capecitabine combined 
with trastuzumab[68]. Although the therapy was well 
tolerated, progression-free and overall survivals were 
not favorable compared to standard chemotherapy. 
At present, there is no consensus on the treatment 
modalities of HER2-positive pancreatic ductal ADC.
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Figure 3  Representative micrographs of a gastric adenocarcinoma 
showing heterogeneous erbB2 immunohistochemical expression. In this 
paradigmatic example of HER2 heterogeneity in gastric cancer, the tumor 
showed the coexistence of 2+ (A), 3+ (B, C), and negative areas (C), with the 
former immunohistochemical pattern involving the majority of the tumor cells. 
Original magnification × 200.
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Hepatocellular carcinoma
Hepatocellular carcinoma (HCC), is the fifth most 
common cancer in men and the seventh most common 
cancer in women, resulting in approximately 700000 
deaths yearly[32]. In recent years, these tumors showed 
increasing incidence, albeit variable throughout the 
world[32,69]. The asymptomatic nature of early disease 
and the limited use of screening protocols in high-
risk individuals often lead to diagnosis in advanced 
stages, with subsequent requirement of systemic 
therapy[70,71]. To date, sorafenib (a kinase inhibitor) 
is the only approved drug in patients with advanced 
HCC, with modest effectiveness at prolonging patients’ 
overall survival[72,73]. Given the scarce therapeutic 
armamentarium currently available, capturing the 
complexity underpinning HCC biology represents a 
high-priority goal[70]. In this setting, the role of HER2 
in HCC has been explored in several studies yielding, 
however, to extremely discrepant results due to 
the diverse methods used for HER2 testing, even 
including cytoplasmic expression[74-76]. It is currently 
recognized that there is a low frequency of erbB2 
strong membranous IHC overexpression in HCC[77-79]. 
Among these few cases, only a minority of tumors is 
reported to harbor HER2 amplification[80,81]. Therefore, 
it is unlikely that patients with HCC would benefit from 
treatment with trastuzumab. In addition, recent studies 
suggest that there is also little indication for using HER2 
as a prognostic biomarker in these tumors[79].
Biliary tract cancer
Biliary tract cancer (BTC) encompasses a hetero-
geneous group of rare tumors originating in either 
the intra- or extrahepatic ducts[20]. This collection of 
neoplasms includes cholangiocarcinoma, gallbladder 
cancer (GBC), and ampulla of Vater cancer[20]. Among 
them, GBC is the most frequent type with an annual 
incidence of 2.5 cases per 100000 individuals[32]. Taken 
together, BTC mortality varies between geographic 
areas, accounting for higher mortality rates in South 
America and South-East Asia[69]. The current state-of-
knowledge on BTC, regrettably, can be summarized 
briefly: complete tumor resection is the best chance 
of survival[82]. However, most cases are detected 
at an advanced stage, when surgical approaches 
are no longer feasible, and recurrences and distant 
metastases are common, with subsequent poor 
survival rates[82]. In addition, adjuvant chemotherapy 
has not shown sufficient benefit for BTC, while the 
efficacy of molecular targeted agents is still extremely 
disappointing[83,84]. To improve the prognosis of BTC, 
identification of prognostic markers and effective 
therapeutic targets is essential[85]. BTCs showing erbB2 
overexpression and/or HER2 amplification range 
between 5% and 76%[86], including an estimated 13% 
of erbB2-positive GBC[87]. This wide range is largely 
dependent upon the lack of standardized methods 
used among different studies[27,88]. Intratumor erbB2-
expression heterogeneity has not been investigated 
thoroughly in BTC[75,86,88-90]. However, 51% of cases 
in a small cohort study showed erbB2 positivity using 
50% of positive tumor cells as a threshold, suggesting 
the presence of heterogeneous protein expression[27]. 
Furthermore, in this subset of tumors, 83% of cases 
with heterogeneous erbB2 immunohistochemical 
(IHC) overexpression displayed HER2 amplification by 
fluorescent in situ hybridization (FISH)[27]. Nevertheless, 
no data regarding HER2 amplification heteroge-
neity have been reported in literature. The highest 
concordance between erbB2 expression and gene 
amplification was demonstrated for advanced BTC with 
high scores of erbB2 expression in the vast majority of 
tumors cells, present only in a minority of cases[68,88]. 
Taking into account overall and disease-free survival, 
HER2 amplification seems not to have a prognostic 
role in BTC[27]. On the other hand, form a therapeutic 
standpoint, a subset of HER2-positive GBC responded 
well to trastuzumab treatment, both in monotherapy 
and in combination with taxane[85,90-92]. Despite these 
encouraging observations, an early phase clinical trial 
of trastuzumab for HER2-positive locally advanced or 
metastatic GBC was terminated in the United States 
because of the lack of participants (https://clinicaltrials.
gov/ct2/show/study/NCT00478140). In this respect, it 
would be extremely beneficial to involve countries with 
a higher incidence of BTC in large-cohort clinical trials. 
FROM TRADITIONAL PATHOLOGY TO 
MOLECULAR CHARACTERIZATION
Determination of HER2 status and its clinical 
significance
These data highlight that erbB2 overexpression and/or 
HER2 amplification occur more frequently in ADC 
of the upper gastrointestinal tract compared to the 
rest of the DSC. In routine diagnostic practice and in 
research settings, erbB2 IHC scoring, along with the 
assessment of other prognostic and predictive factors, 
remains a cornerstone in the DSC pathology[44,57,93,94]. 
At present, it is taking place a consensus in extending 
the scoring system currently adopted in gastric ADC 
for all other DSC[57]. Compared to the breast, erbB2 
IHC in DSC has a few substantial differences not only 
from intra- and inter-tumor heterogeneity standpoints 
but also in terms of cellular staining patterns. Indeed, 
erbB2 expression is mainly restricted to intestinal-type, 
gland-forming GC, and incomplete, often basolateral 
or even only lateral membranous IHC staining is 
the rule rather than an exception for HER2-positive 
GC[93,95]. Hence, circularity of IHC staining is no longer a 
criterion for erbB2 IHC scoring in the digestive tract[95]. 
A cornerstone work on esophageal ADC aimed to 
compare the erbB2 scoring system routinely employed 
in the breast to that used in GC[96,97]. However, no 
similar studies have been performed on other DSCs, 
therefore further analyses are warranted. In this era 
7931 September 21, 2016|Volume 22|Issue 35|WJG|www.wjgnet.com
Fusco N et al . HER2  in digestive system cancers
of precision medicine, there are increasing evidences 
that digital image analysis tools are able to capture the 
whole spectrum of erbB2 IHC expression patterns and 
therefore represent useful tools for determining HER2 
status and its heterogeneity in DSC[12,98,99]. Both the 
membranous and nuclear features of the cells should 
be identified and scored, while the settings for cell 
count and differentiation between stroma and neoplasia 
should take into account the morphologic features 
of the cells (e.g., curvature, color intensity, size, 
roundness, compactness, elongation) as well as each 
histologic pattern (e.g., glandular, solid). Digital image 
analysis technologies grant a rapid and quantitative 
record of the percentage of stained tumor cells and 
their membrane staining distribution, allowing a precise 
and reproducible patients’ stratification also capturing 
intra-tumor heterogeneity[12]. To verify equivocal 
IHC results, FISH, silver in situ hybridization (SISH), 
chromogenic in situ hybridization (CISH) assays are 
widely performed[8,12,57,93,96]. In particular, FISH identifies 
the number of HER2 gene copies in conjunction with 
the number of chromosome 17 centromere (CEP17) 
copies[94]. This scoring is considered more objective and 
quantitative than IHC, however FISH reproducibility is 
strictly dependent on technical issues (e.g., thickness 
of tissue sections)[8,100-103]. On the other hand, CISH 
is re-emerging as a more cost-effective assay, using 
conventional enzymatic reactions and being applicable 
to standard formalin-fixed paraffin embedded (FFPE) 
tissues[104]. This method shows high levels of quality 
and reproducibility, particularly in GC[105]. In a way akin 
to CISH, SISH is a rapid automated assay that can be 
interpreted using conventional microscopies, allowing 
pathologists to evaluate HER2 status within the context 
of tissue morphology[103,106].
Overcoming resistance to erbB2-targeted therapies 
Resistance to trastuzumab and other anti-erbB2 the-
rapies is an event that may occur during the course 
of therapy or de novo (Table 2)[107]. Drug resistance 
has been widely studied in breast cancer but not in 
the DSC, with subsequent lack of a detailed molecular 
characterization of this phenomenon. Intra-tumor and 
tumor-to-metastasis heterogeneity are among the most 
important characteristics that determine resistance 
to anti-erbB2 therapy in DSC and should always be 
taken into account when selecting patients eligible for 
these treatments and clinical trials[12,19,52,96,108]. Indeed, 
there are several molecular evidences that genetic 
heterogeneity is not restricted to passenger genes 
but that also bona fide driver genetic alterations such 
as HER2 gene amplification can be heterogeneously 
distributed within a given tumor[109]. The therapeutic 
implications of this concept are yet to be ascertained, 
although it is intuitive that only the HER2-positive 
neoplastic population would be sensitive to anti-
erbB2 drugs[110]. Furthermore, it is not clear whether 
HER2 amplification is an early event and subsequently 
lost in the HER2-negative components, or whether 
HER2 amplification might be subclonally acquired at a 
relatively late stage of tumorigenesis[12,27]. In addition, 
somatic mutations in HER2 have been described 
in a small subset of DSC and there are functional 
evidences that at least a subset of mutations targeting 
HER2 might be responsible for the development of 
resistance to trastuzumab therapy, in a way akin to 
breast cancer[8,109]. For example, alterations leading to 
increased heterodimerization of HER2 with EGFR or 
HER3 are thought to induce resistance to trastuzumab 
therapy[107]. Furthermore, cleavage of the full-length 
erbB2 protein produces a truncated membrane-
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Table 2  Mechanisms of resistance occurring in erbB2-tageting agents[107]
Type Agent Target Mechanisms of resistance Factors involved
Monoclonal antibodies Trastuzumab erbB2 Alterations in tyrosine kinase domain; 
overexpression of alternative erbB 
isoforms and dimerization receptors; loss 
of downstream checkpoints; dimerization 
and interaction with other receptors
p95HER2, MUC4 EGFR, erbB 
ligands (TGFa, EGF, HB), 
PTEN IGF1R, MET
Pertuzumab erbB2
T-DM1 erbB2
Tyrosine kinase inhibitors Lapatinib erbB1, erbB2 Alterations in tyrosine kinase domain; 
acquisition of HER2 mutations; activation 
of further downstream signaling 
pathways
KIT and PDGFRA receptor 
signaling pathway; PI3K-
AKT, mTOR
Neratinib erbB2, erbB4
Afatinib erbB1, erbB2, erbB4
Canertinib erbB1, erbB2, erbB4
Inhibitors of the downstream 
targets
Everolimus mTOR Activation of further downstream 
signaling pathways
PI3K-AKT, mTOR, MEK, 
MAPKBKM120 PI3K/AKT
BEZ-235 PI3K/AKT/mTOR
GS-1101 PI3K
NVP-BKM120 PI3K
GDC-0941 PI3K
GSK458 PI3K/mTOR
GDC-0980 PI3K/mTOR
PI-103 PI3K/mTOR
hsp90 inhibitors Tanespimycin hsp90 Up-regulation of alternative pathways NF-κB, MAPK
Retaspimycin hsp90
AUY922 hsp90
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associated fragment called p95HER2 with increased 
kinase activity in GC cell lines[111,112]. Up to 30% of 
breast cancers may harbor this alteration, showing 
poor prognosis and lower rates of response to trastu-
zumab therapy compared to patients with full-length 
HER2[111]. Furthermore, 11% of HCC but none of BTC 
have been found to harbor HER2 (H878Y) somatic 
mutation occurring in the tyrosine kinase domain, 
resulting in c.2632C>T[81,113,114]. This specific mutation 
has been proposed as a predictor of response to HER2- 
and/or EGFR-targeted therapy in HCC. Interestingly, 
a phase Ⅱ trial observed that the dual EGFR/HER2 
tyrosine kinase inhibitor lapatinib was active in HCC 
but not in BTC, suggesting that mutations in the 
tyrosine kinase domain of HER2 in HCC may underlie 
responsiveness to agents that target HER2 and/or 
EGFR[115]. Generally, erbB2-directed therapy appears 
to be beneficial in erbB2-positive gallbladder cancers; 
however, tumors harboring HER2 mutation (V777L), in 
the kinase domain, followed into the non-responders 
category[91]. In addition to the alterations in erbB2 
receptors, mutations in genes involved in the signaling 
pathways activated by these receptors are also 
correlated with failure of therapeutic response to erbB2 
inhibitors[116]. A preclinical trial is testing the hypothesis 
that HER2 amplification might be used, under certain 
conditions, as a “molecular bait” for trastuzumab-
emtansine precision chemotherapy to overcome anti-
erbB2 resistance in HER2-positive metastatic CRC[117]. 
Moreover, PIK3CA mutations and PTEN inactivation 
could affect the effectiveness of erbB2-targeting 
therapy. Thus, it might be advantageous to clarify not 
only HER2 alterations but also the PI3K-Akt pathway 
status to optimize HER2-targeting therapy[118]. In this 
regard, massively parallel sequencing and bioinformatic 
analyses are likely to represent the next frontier in the 
identification of complex mechanisms of trastuzumab 
resistance in this broad group of tumors[8,118-120]. A better 
knowledge of the biology underpinning HER2 status in 
the digestive system should be regarded as a priority 
for the development of effective strategies to overcome 
resistance.
CONCLUSIONS: BUILDING UP 
INDIVIDUAL THERAPEUTIC SCHEMES 
Substantial progress has been made in the mana-
gement of patients with advanced-stage DSC in recent 
years, with the realization of tangible improvements 
in terms of outcome and life quality. In particular, 
trastuzumab has greatly improved the therapeutic 
approach to patients with advanced GC but not yet 
in other DSC. However, no validated HER2 testing 
strategies are available for non-gastric DSC and 
subsequently tailored treatments are yet to be imple-
mented in this broad group of malignancies. Several 
drugs targeting erbB2 or its downstream signals are 
under development in CRC, GBC, and EC, including 
ongoing phase 3 clinical trials in CRC. Nowadays, the 
focus on HER2 expression/amplification status alone 
is not able to capture the underlying mechanisms of 
disease progression and resistance. In this setting, 
PIK3CA mutation or PTEN loss has been evaluated 
as a possible predictive biomarker and has also been 
used as one of the inclusion criteria. Understanding 
the interplay between HER2 and the PI3K-Akt pathway 
alterations would be pivotal in the development of 
new therapeutic strategies. Further studies focused 
on the epistasis between molecular alterations and 
associations between molecular alterations and tumor 
microenvironment are warranted to accurately and 
robustly predict anti-erbB2 treatment outcome in DSC. 
Thus, a comprehensive clinical and pathogenomic 
approach is fundamental in appropriately characterizing 
HER2 status in DSC at an individualized level for both 
precision therapy and accurate prognostication.
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